Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GCG | P01275 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.43 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2099967 | 0.88 | ALDH1A1 (0.58) | ALDH1A1MMEL1 | |
| SCHEMBL2101868 | 0.86 | PTGDR2 (0.57) | PTGDR2TDP1TSHRGCGAKR1B1 | |
| SCHEMBL2102259 | 0.85 | ALDH1A1 (0.50) | PTGDR2ALDH1A1TSHRGCG | |
| SCHEMBL2100684 | 0.82 | HTT (0.46) | ALDH1A1GCG | |
| SCHEMBL2102664 | 0.76 | PTGDR2 (0.54) | PTGDR2TDP1TSHR | |
| SCHEMBL2103013 | 0.75 | TSHR (0.49) | PTGDR2ALDH1A1TSHRGCG | |
| SCHEMBL1753654 | 0.74 | PTGDR2 (0.85) | PTGDR2TDP1TSHR | |
| SCHEMBL3343607 | 0.73 | LMNA (0.70) | ALDH1A1TSHRGCG | |
| SCHEMBL2101408 | 0.73 | LMNA (0.53) | PTGDR2ALDH1A1TSHRGCG | |
| SCHEMBL1753554 | 0.72 | PTGDR2 (0.68) | PTGDR2TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784388-B3 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | claimed |
| US-20120178732-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | LUKER TIMOTHY JON (GB) | 2012-07-12 | — | — | US | claimed |
| US-20100160285-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | claimed |
| EP-1784388-B1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2009-11-04 | — | — | EP | claimed |
| US-20080132480-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | claimed |
| US-8722741-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2014-05-13 | — | — | US | disclosed |
| US-8722741-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2014-05-13 | — | — | US | disclosed |
| US-8722741-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2014-05-13 | — | — | US | disclosed |
| EP-1784388-B3 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| EP-1784388-B3 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120178732-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | LUKER TIMOTHY JON (GB) | 2012-07-12 | — | — | US | disclosed |
| US-20120178732-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | LUKER TIMOTHY JON (GB) | 2012-07-12 | — | — | US | disclosed |
| US-7737135-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| EP-1784388-B1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2009-11-04 | — | — | EP | disclosed |
| EP-1784388-B1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2009-11-04 | — | — | EP | disclosed |
| US-20080132480-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20080132480-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20080132480-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| EP-1784388-A1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | AstraZeneca AB (SE) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021759-A1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178732-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | CYP26A1, CYP1A1, GPBAR1 | PTGDR2 724/4885ALDH1A1 42/4885TDP1 3295/4885 |
| US-20100160285-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | CYP26A1, CYP1A1, GPBAR1 | PTGDR2 724/4885ALDH1A1 42/4885TDP1 3295/4885 |
| US-20080132480-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | CYP26A1, CYP1A1, GPBAR1 | PTGDR2 724/4885ALDH1A1 42/4885TDP1 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.